Open AccessRANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Author(s) -
Frank G. Holz,
Marta S. Figueroa,
Francesco Bandello,
Yit Yang,
Masahito Ohji,
Hong Dai,
Halina Wykrota,
Sanjay Sharma,
Cornelia DungerBaldauf,
Sue Lacey,
Wayne Macfadden,
Paul Mitchell
Publication year - 2019
Publication title -
retina
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.24
H-Index - 120
eISSN - 1539-2864
pISSN - 0275-004X
DOI - 10.1097/iae.0000000000002670
Subject(s) - medicine , ranibizumab , macular degeneration , visual acuity , ophthalmology , adverse effect , incidence (geometry) , prospective cohort study , demographics , surgery , bevacizumab , chemotherapy , physics , demography , sociology , optics
To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naive patients with neovascular age-related macular degeneration enrolled in LUMINOUS study.